Join the Insightful Webinar on the Future of Psychedelics
Clearmind Medicine Inc. (NASDAQ: CMND), a pioneering clinical-stage biotech company engaged in the discovery and development of novel psychedelic-derived therapeutics, is thrilled to announce an upcoming live event titled "Gazing Through the Crystal Ball." This enlightening webinar is set to take place at 12 PM ET on an upcoming date, bringing together a panel of esteemed experts who will delve into the dynamic realm of psychedelic science and its evolving business landscape amidst shifting regulatory climates.
Unveiling Psychedelic Innovation
Throughout the session, attendees will be introduced to leading voices in the psychedelic research community. Notable speakers scheduled to participate include Rick Doblin, PhD, a visionary in the field and the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS). Dr. Doblin's work has been foundational in advocating for the safe and ethical application of psychedelics.
Contributing Perspectives from Experts
Joining Dr. Doblin will be Robin Carhart-Harris, PhD, renowned for his groundbreaking work in psychedelic neuroscience at the University of California, San Francisco (UCSF). Dr. Carhart-Harris has led pivotal studies on psilocybin and its therapeutic potential, contributing significantly to the understanding of psychedelic compounds.
Dr. Adi Zuloff-Shani, the CEO of Clearmind Medicine, will also share insights into the company's mission and innovations. With a focus on developing treatment options for Alcohol Use Disorder (AUD), he is at the forefront of advancing Clearmind's groundbreaking therapy, CMND-100, which has obtained regulatory approval for clinical trials.
Panel Discussion and Moderator Insights
The insightful dialogue will be moderated by Shannon Smadella, a prominent wellness advocate and podcast host who has made significant contributions to the psychedelic conversation through initiatives like World Psychedelics Day. Her expertise in public engagement is sure to enrich the discussion.
How to Participate
Interested individuals are encouraged to register for the webinar through Clearmind’s official website. This event promises to be a valuable opportunity for anyone looking to explore the current trends and future directions in psychedelic science.
About Clearmind Medicine Inc.
Clearmind Medicine is dedicated to addressing pressing health challenges with its groundbreaking psychedelic therapies. The company aims to bring innovative solutions to the therapeutic landscape, focusing on areas that are significantly underrepresented in traditional medicine, such as alcohol use disorder.
With an impressive intellectual property portfolio, including nineteen patent families and 31 granted patents, Clearmind is poised to expand its innovations and contribute to the evolving landscape of psychedelic treatments.
Stay Connected
Share in the journey of Clearmind Medicine as it navigates the complexities of regulatory environments and advances research aimed at improving patient health through psychedelics. For media inquiries or additional information, please reach out via the provided contact details.
The shares of Clearmind are publicly traded on Nasdaq under the symbol "CMND". As they continue to make strides in the industry, keep an eye on their developments and progress.
Frequently Asked Questions
What is the "Gazing Through the Crystal Ball" webinar about?
This upcoming webinar focuses on psychedelic science, featuring discussions from leading experts in the field.
When will the webinar take place?
The webinar is scheduled for 12 PM ET on a designated date. Register for specific timing details.
Who are the featured speakers?
Speakers include Rick Doblin, Robin Carhart-Harris, and Dr. Adi Zuloff-Shani, among others.
How can I register for the webinar?
Registration can be completed through the Clearmind Medicine website.
What topics will be discussed during the webinar?
Discussion topics will include the evolving landscape of psychedelic science, regulatory changes, and future opportunities in therapeutic development.
